HPE HPE Fresenius Kabi handbook - Page 20

TABLE 1 Authorised biosimilars (to October 2018) (Continued) Product name INN/active substance Therapeutic area Marketing authorisation holder Marketing authorisation date Flixabi Infliximab Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, Crohn’s disease, ankylosing spondylitis Samsung Bioepis UK Limited 26/5/2016 Inhixa Enoxaparin sodium Venous thromboembolism Techdow Europe AB 15/9/2016 Thorinane Enoxaparin sodium Venous thromboembolism Pharmathen SA 15/9/2016 Lusduna Insulin glargine Diabetes MSD 04/01/2017 Terrosa Teriparatide Osteoporosis Gedeon Richter 04/01/2017 Movymia Teriparatide Osteoporosis Stada Arzneimittel 11/01/2017 Truxima Rituximab Chronic lymphocytic leukaemia, granulomatosis with polyangiitis, microscopic polyangiitis, non- Hodgkin’s lymphoma, rheumatoid arthritis Celltrion 17/02/2017 Amgevita Adalimumab Ankylosing spondylitis, Crohn’s disease, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis Amgen 22/03/2017 Solymbic Adalimumab Ankylosing spondylitis, Crohn’s disease, hidradenitis suppurativa, psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis Amgen 22/03/2017 Flixabi Infliximab Ankylosing spondylitis, Crohn’s disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, ulcerative colitis Samsung Bioepis 26/05/2017 Riximyo Rituximab Chronic B-cell lymphocytic leukaemia, microscopic polyangiitis, non-Hodgkin lymphoma, rheumatoid arthritis, Wegener granulomatosis Sandoz 15/06/2017 Rixathon Rituxumab Chronic B-cell lymphocytic leukaemia, microscopic polyangiitis, non-Hodgkin lymphoma, rheumatoid arthritis, Wegener granulomatosis Sandoz 19/06/2017 Erelzi Etanercept Ankylosing spondylitis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis Sandoz 23/06/2017 20 | 2019 | hospitalpharmacyeurope.com